← Back to Screener
US Stock Screener
HomeScreensNewsWatchlist
...

Nurix Therapeutics, Inc. (NRIX) 10-Year Financial Performance & Capital Metrics

NRIX •
HealthcareBiotechnologyDrug Discovery and Antibody Platforms
AboutNurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally available Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications. It also develops NX-0255, a CBL-B inhibitor for ex vivo use to enhance adoptive T-cell therapy; and DeTIL-0255 that is in the Phase 1 clinical trial for the treatment of gynecologic cancers, including ovarian, endometrial, and cervical cancer. The company has a strategic collaboration agreement with Gilead Sciences, Inc. for cancer and other challenging diseases patients; and Sanofi S.A. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. The company was incorporated in 2009 and is headquartered in San Francisco, California.Show more
  • Revenue $84M +54.0%
  • EBITDA -$267M -30.1%
  • Net Income -$264M -36.6%
  • EPS (Diluted) -3.05 -5.9%
  • Gross Margin 77.55% +125.3%
  • EBITDA Margin -317.71% +15.5%
  • Operating Margin -340.16% +12.9%
  • Net Margin -314.9% +11.3%
  • ROE -49.63% +6.7%
  • ROIC -54.05% -5.2%
  • Debt/Equity 0.10 +92.6%
  • Interest Coverage -
Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

  • ✓Strong 5Y sales CAGR of 36.3%

✗Weaknesses

  • ✗Negative free cash flow
  • ✗Shares diluted 29.1% in last year
  • ✗Low asset turnover indicates capital-intensive operations

* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-
5Y36.35%
3Y29.55%
TTM53.95%

Profit (Net Income) CAGR

10Y-
5Y-
3Y-
TTM-36.62%

EPS CAGR

10Y-
5Y-
3Y-
TTM-5.19%

ROCE

10Y Avg-56.35%
5Y Avg-45.84%
3Y Avg-49.89%
Latest-48.62%

Peer Comparison

Drug Discovery and Antibody Platforms
Select Columns
Size & Scale
Valuation
Per Share
Growth
Profitability
Quality & Returns
Safety & Leverage
TTM Growth
Famous Investor Metrics
Dividends
Latest Quarter
Momentum & Returns
Total Return (DRIP)
Technical
Volume & Trading
Shares & Dilution
Sector-Specific
NameMarket CapCurrent PriceP/E RatioRevenue Growth 1YNet MarginROEFCF YieldDebt/Equity
REGNRegeneron Pharmaceuticals, Inc.107.56B781.6718.840.99%31.41%14.41%3.79%0.09
CTMXCytomX Therapeutics, Inc.430.14M5.3714.1336.45%24.66%26.09%
PRTCPureTech Health plc405.3M16.778.3944.98%-495.91%-8.53%0.05
DNAGinkgo Bioworks Holdings, Inc.327.53M6.75-1.20-25.06%-183.81%-61.5%0.82
BCYCBicycle Therapeutics plc111.38M5.73-1.9830.76%-8.85%-40.53%0.01
CCCCC4 Therapeutics, Inc.261.67M2.70-2.13-100%-40.92%0.23
MOLNMolecular Partners AG187.84M5.02-2.43-29.38%-10.87%-63.06%0.02
RXRXRecursion Pharmaceuticals, Inc.1.94B3.67-2.5526.92%-8.65%-57.01%0.07

Compare NRIX vs Peers

Analyze head-to-head performance against top industry competitors across valuation, growth, and profitability metrics.

vs REGN

Compare head-to-head with Regeneron Pharmaceuticals, Inc.

vs CNTA

Compare head-to-head with Centessa Pharmaceuticals plc

Compare Top 5

vs REGN, CNTA, IMNM, CLDX

Profit & Loss

Nov 2018Nov 2019Nov 2020Nov 2021Nov 2022Nov 2023Nov 2024Nov 2025
Sales/Revenue+37.45M31.11M17.82M29.75M38.63M76.99M54.55M83.98M
Revenue Growth %--16.91%-42.73%66.95%29.84%99.31%-29.15%53.95%
Cost of Goods Sold+40.51M45.02M66.49M116.43M184.5M189.15M221.63M18.86M
COGS % of Revenue108.18%144.71%373.14%391.37%477.64%245.69%406.3%22.45%
Gross Profit+-3.06M-13.91M-48.67M-86.68M-145.87M-112.16M-167.08M65.12M
Gross Margin %-8.18%-44.71%-273.14%-291.37%-377.64%-145.69%-306.3%77.55%
Gross Profit Growth %--353.83%-249.92%-78.09%-68.28%23.11%-48.97%138.98%
Operating Expenses+6.67M8.33M16.31M31.2M38M42.9M45.94M350.79M
OpEx % of Revenue17.82%26.76%91.52%104.88%98.37%55.73%84.23%417.71%
Selling, General & Admin6.67M8.33M16.31M31.2M38M42.9M45.94M52.74M
SG&A % of Revenue17.82%26.76%91.52%104.88%98.37%55.73%84.23%62.8%
Research & Development40.51M45.02M66.49M116.43M184.5M189.15M221.63M308.16M
R&D % of Revenue108.18%144.71%373.14%391.37%477.64%245.69%406.3%366.95%
Other Operating Expenses-40.51M-45.02M-66.49M-116.43M-184.5M-189.15M-221.63M-10.12M
Operating Income+-9.74M-22.24M-64.98M-117.89M-183.87M-155.06M-213.03M-285.67M
Operating Margin %-26.01%-71.46%-364.66%-396.26%-476.01%-201.41%-390.52%-340.16%
Operating Income Growth %--128.32%-192.24%-81.41%-55.97%15.67%-37.38%-34.1%
EBITDA+-6.75M-19.88M-62.8M-115.9M-179.72M-148.93M-205.01M-266.81M
EBITDA Margin %-18.03%-63.9%-352.43%-389.57%-465.27%-193.45%-375.83%-317.71%
EBITDA Growth %--194.5%-215.88%-84.54%-55.07%17.13%-37.65%-30.15%
D&A (Non-Cash Add-back)2.99M2.35M2.18M1.99M4.15M6.13M8.02M18.86M
EBIT-9.74M-22.24M-64.98M-117.89M-183.87M-155.06M-213.03M-263.7M
Net Interest Income+818K776K1.21M823K3.51M11.12M19.73M21.97M
Interest Income818K776K1.21M823K3.51M11.12M19.73M21.97M
Interest Expense00000000
Other Income/Expense818K776K1.21M823K3.51M11.12M19.73M21.97M
Pretax Income+-8.92M-21.46M-63.78M-117.06M-180.36M-143.95M-193.3M-263.7M
Pretax Margin %-23.82%-68.97%-357.9%-393.49%-466.93%-186.98%-354.36%-314%
Income Tax+507K239K-20.54M131K00270K760K
Effective Tax Rate %105.68%101.11%67.8%100.11%100%100%100.14%100.29%
Net Income+-9.43M-21.7M-43.24M-117.19M-180.36M-143.95M-193.57M-264.46M
Net Margin %-25.18%-69.74%-242.66%-393.93%-466.93%-186.98%-354.85%-314.9%
Net Income Growth %--130.15%-99.28%-171.02%-53.9%20.19%-34.47%-36.62%
Net Income (Continuing)-9.43M-21.7M-43.24M-117.19M-180.36M-143.95M-193.57M-264.46M
Discontinued Operations00000000
Minority Interest00000000
EPS (Diluted)+-0.59-0.56-2.76-2.73-3.71-2.65-2.88-3.05
EPS Growth %-5.08%-392.86%1.09%-35.9%28.57%-8.68%-5.9%
EPS (Basic)-0.59-0.56-2.76-2.73-3.71-2.65-2.88-3.05
Diluted Shares Outstanding16.11M38.85M15.67M42.9M48.61M54.34M67.12M86.67M
Basic Shares Outstanding16.11M38.85M15.67M42.9M48.61M54.34M67.12M86.67M
Dividend Payout Ratio--------

Balance Sheet

Nov 2018Nov 2019Nov 2020Nov 2021Nov 2022Nov 2023Nov 2024Nov 2025
Total Current Assets+40.65M39.35M298.43M311.12M318.45M295.5M619.39M606.82M
Cash & Short-Term Investments39.04M37.72M281.15M295.72M309.14M287.91M609.58M592.94M
Cash Only25.59M34.82M119.36M80.51M64.47M54.63M110M246.96M
Short-Term Investments13.45M2.9M161.79M215.21M244.67M233.28M499.59M345.98M
Accounts Receivable0011.35M6.2M1.1M800K1.5M0
Days Sales Outstanding--232.476.1210.393.7910.04-
Inventory0000-1.1M000
Days Inventory Outstanding--------
Other Current Assets000900K9.31M6.79M8.3M13.88M
Total Non-Current Assets+4.74M4.69M97.91M165.65M98.31M60.09M49.96M81.32M
Property, Plant & Equipment4.42M3.87M6.67M25.34M29.51M47.95M45.9M73.01M
Fixed Asset Turnover8.47x8.04x2.67x1.17x1.31x1.61x1.19x1.15x
Goodwill00000000
Intangible Assets00000000
Long-Term Investments170K506K90.89M137.47M63.88M7.42M00
Other Non-Current Assets151K317K347K3.12M4.92M4.72M4.06M8.31M
Total Assets+45.4M44.05M396.34M476.77M416.76M355.6M669.34M688.13M
Asset Turnover0.82x0.71x0.04x0.06x0.09x0.22x0.08x0.12x
Asset Growth %--2.97%799.8%20.29%-12.59%-14.68%88.23%2.81%
Total Current Liabilities+32.83M16.14M44.54M66.26M70.66M86.96M95.85M86.47M
Accounts Payable1.3M1.6M3.41M6.65M5.06M6.4M11.48M11.21M
Days Payables Outstanding11.6912.9518.7320.8510.0212.3518.91217.09
Short-Term Debt0003.85M5.53M7.49M00
Deferred Revenue (Current)28.42M9.61M32.8M41.21M37.63M48.1M38.36M17.58M
Other Current Liabilities726K1.18M2.6M5.67M9.14M751K18.91M23.64M
Current Ratio1.24x2.44x6.70x4.70x4.51x3.40x6.46x7.02x
Quick Ratio1.24x2.44x6.70x4.70x4.52x3.40x6.46x7.02x
Cash Conversion Cycle--------
Total Non-Current Liabilities+49.41M85.63M61.53M68.21M42.41M68.15M46.5M62.92M
Long-Term Debt00000000
Capital Lease Obligations0009.19M6.43M23.13M20.29M52.91M
Deferred Tax Liabilities00000000
Other Non-Current Liabilities1.22M1.74M850K00000
Total Liabilities34.05M53.57M106.07M134.47M113.06M155.1M142.35M149.39M
Total Debt+00013.04M11.96M30.61M28.3M55.73M
Net Debt-25.59M-34.82M-119.36M-67.47M-52.51M-24.01M-81.69M-191.23M
Debt / Equity---0.04x0.04x0.15x0.05x0.10x
Debt / EBITDA--------
Net Debt / EBITDA--------
Interest Coverage--------
Total Equity+-36.85M-57.71M290.27M342.3M303.7M200.49M526.99M538.75M
Equity Growth %--56.63%602.94%17.93%-11.28%-33.98%162.85%2.23%
Book Value per Share-2.29-1.4918.527.986.253.697.856.22
Total Shareholders' Equity-36.85M-57.71M290.27M342.3M303.7M200.49M526.99M538.75M
Common Stock3K4K39K45K47K49K76K102K
Retained Earnings-38.76M-60.46M-103.7M-220.89M-401.25M-545.2M-738.77M-1B
Treasury Stock-1.9M0000000
Accumulated OCI-4K-2K87K-608K-4.32M-655K150K105K
Minority Interest00000000

Cash Flow

Nov 2018Nov 2019Nov 2020Nov 2021Nov 2022Nov 2023Nov 2024Nov 2025
Cash from Operations+-31.68M601K-80K-84.36M-159.81M-81.36M-172.58M-249.47M
Operating CF Margin %-84.58%1.93%-0.45%-283.58%-413.72%-105.69%-316.38%-297.05%
Operating CF Growth %-101.9%-113.31%-105356.25%-89.42%49.09%-112.11%-44.55%
Net Income-9.43M-21.7M-43.24M-117.19M-180.36M-143.95M-193.57M-264.46M
Depreciation & Amortization2.99M2.35M2.18M6.08M10.81M13.65M16.43M18.86M
Stock-Based Compensation431K510K4.3M15.8M28.13M33.67M33.93M37.97M
Deferred Taxes-354K0000000
Other Non-Cash Items-6K-109K273K1.83M636K-4.87M-10.97M-10.23M
Working Capital Changes-25.31M19.55M36.41M9.11M-19.02M20.12M-18.4M-31.6M
Change in Receivables12.37M0-11.35M-6M6M000
Change in Inventory0006.77M0000
Change in Payables-519K302K1.23M1.59M85K1.61M5.21M-630K
Cash from Investing+39.99M8.5M-254.4M-108.25M27.2M68.3M-257.71M147.85M
Capital Expenditures-1.59M-1.65M-4.55M-5.66M-12.24M-8.4M-9.27M-14M
CapEx % of Revenue4.26%5.31%25.55%19.03%31.7%10.91%17%16.67%
Acquisitions6K-10.15M249.85M102.59M-39.44M000
Investments--------
Other Investing010.15M-249.85M-102.59M39.44M000
Cash from Financing+529K126K339.02M153.88M117.19M3.22M485.67M238.64M
Debt Issued (Net)00000000
Equity Issued (Net)529K126K1000K1000K1000K1000K1000K1000K
Dividends Paid00000000
Share Repurchases-2K-16K-7K00000
Other Financing00963K3.73M97.79M07.17M0
Net Change in Cash8.85M9.22M84.54M-38.73M-15.42M-9.85M55.37M137.03M
Free Cash Flow+-33.27M-1.05M-4.63M-90.03M-172.05M-89.77M-181.86M-263.47M
FCF Margin %-88.84%-3.37%-26%-302.61%-445.42%-116.6%-333.38%-313.73%
FCF Growth %-96.84%-341.24%-1843.15%-91.11%47.83%-102.59%-44.88%
FCF per Share-2.07-0.03-0.30-2.10-3.54-1.65-2.71-3.04
FCF Conversion (FCF/Net Income)3.36x-0.03x0.00x0.72x0.89x0.57x0.89x0.94x
Interest Paid00000000
Taxes Paid1K1K1K481K0000

Key Ratios

Metric20182019202020212022202320242025
Return on Equity (ROE)---37.19%-37.05%-55.84%-57.1%-53.22%-49.63%
Return on Invested Capital (ROIC)---124.36%-39.67%-52.43%-54.39%-51.39%-54.05%
Gross Margin-8.18%-44.71%-273.14%-291.37%-377.64%-145.69%-306.3%77.55%
Net Margin-25.18%-69.74%-242.66%-393.93%-466.93%-186.98%-354.85%-314.9%
Debt / Equity---0.04x0.04x0.15x0.05x0.10x
FCF Conversion3.36x-0.03x0.00x0.72x0.89x0.57x0.89x0.94x
Revenue Growth--16.91%-42.73%66.95%29.84%99.31%-29.15%53.95%

Deep Dive Analysis

Explore detailed financial history, valuation models, and returns analysis

Valuation Overview

DCF models, peer multiples & analyst estimates

Total Return Calculator

Historical returns with dividends reinvested

Dividend History

Yield, growth, payout safety & DRIP calculator

Earnings History

EPS trends, net income & profitability analysis

Price History

Long-term charts & historical price data

Revenue History

Sales growth patterns & revenue breakdown

Financial Ratios

30 years of valuation, profitability & efficiency metrics

VCP Scanner

Find stocks. Verify deeply. Act with conviction.

Patterns find ideas. Fundamentals build conviction.

Data updated daily

Quick Links

  • Home
  • Screens
  • Valuation
  • Compare
  • Total Return
  • News
  • Insights
  • Methodology
  • How It Works
  • Profile

Popular Screens

  • VCP Hot
  • VCP Warm
  • Value Screens
  • Growth Screens
  • Momentum Screens
  • Technical Screens
  • Quality Screens

Community

  • Twitter
  • Get Early Access
© 2026 VCP Scanner. All rights reserved.
Made with ❤️ for investors
Not financial advice. Do your own research.